A novel cannabinoid agonist exhibiting over 10-times higher affinity for the CB2 vs. CB1 receptor produced a minimal toxicity to cultured brain slices at micromolar concentrations required to eradicate U87MG glioma cells [19]. The gene discussed is CNR2; the disease is glioma.